Ann: Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA, page-19

" CHM is the most advanced CAR-T company listed on the ASX having actually clinical CAR-T trials running and valued ZERO. The other one is IMU and despite cell therapy and CAR-T are the hottest oncology topics in the US with rising valuations of those comps the 2 ones here are getting smashed. The even more strange thing is that those ASX stocks still at pre-clinical are valued 10-15 more than CHM.

A lot of things are strange ....the share price is a perception of the worth etc

I'm not an expert on Car T .... other than to note what Gilard paid for Kite Pharma 7 years ago .... $11.9 Billion USD

https://www.gilead.com/news-and-pre...iences-to-acquire-kite-pharma-for-119-billion

Sure its an evolving market .... etc etc ...but I trust the scientific people who make their business to work and invest in the world of developing this IP

Sure its a hit and miss business .... but sometimes a generation of a certain IP can be the catalyst to significant change ....and when there are patents in place etc .... things can get pretty interesting

Not everyone's cup of tea ...I get that

However at 1.6- 2 cents etc etc for CHM ...I'm happy to let the dust settle and see what happens

LOL